Practical Methods to Differentiate Thymic Malignancies by Positron-emission Tomography and Tumor Markers

Overview

Journal Surg Today

Specialty General Surgery

Date 2024 Feb 27

PMID 38411770

Authors

Takahiro Yanagihara

Tomoyuki Kawamura

Naoki Maki

Naohiro Kobayashi

Shinji Kikuchi

Yukinobu Goto

Hideo Ichimura

Yukio Sato

Affiliations

Soon will be listed here.

Abstract

Purpose: An accurate diagnosis of thymic malignancies is important, but challenging due to the broad range of differential diagnoses. This study aims to evaluate the efficacy of PET/CT and tumor markers for diagnosing thymic malignancies.

Methods: Patients admitted to our department between January 2012 and December 2021 with primary anterior mediastinal tumors were retrospectively evaluated. We evaluated the relationship between the maximum standardized uptake value (SUVmax), tumor markers, and pathological diagnosis in four groups: thymic carcinoma, thymoma, lymphoma, and others.

Results: In total, 139 patients were included in this study. The SUVmax was significantly higher in lymphoma, thymic carcinoma, and thymoma, in that order. The cytokeratin 19 fragment (CYFRA 21-1) was significantly higher in thymic carcinoma than in the other groups. An ROC curve analysis indicated that the optimal cut-off values of SUVmax for thymic carcinoma plus lymphoma and CYFRA 21-1 for thymic carcinoma were 7.97 (AUC = 0.934) and 2.95 (AUC = 0.768), respectively. Using a combination of cut-off values (SUVmax = 8, CYFRA 21-1 = 3), the accuracy rate for diagnosing thymic carcinoma was 91.4%.

Conclusions: The SUVmax and CYFRA 21-1 levels are significant indicators for the diagnosis of thymic carcinoma. Combining these indicators resulted in a more accurate diagnosis of thymic malignancies, which could facilitate the decision-making process for determining the optimal treatment strategies.

References

Marx A, Chan J, Chalabreysse L, Dacic S, Detterbeck F, French C . The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?. J Thorac Oncol. 2021; 17(2):200-213. DOI: 10.1016/j.jtho.2021.10.010. View

Carter B, Benveniste M, Madan R, Godoy M, de Groot P, Truong M . IASLC/ITMIG Staging System and Lymph Node Map for Thymic Epithelial Neoplasms. Radiographics. 2017; 37(3):758-776. DOI: 10.1148/rg.2017160096. View

Guerrera F, Falcoz P, Moser B, Van Raemdonck D, Bille A, Toker A . Thymomectomy plus total thymectomy versus simple thymomectomy for early-stage thymoma without myasthenia gravis: a European Society of Thoracic Surgeons Thymic Working Group Study. Eur J Cardiothorac Surg. 2021; 60(4):881-887. PMC: 10060729. DOI: 10.1093/ejcts/ezab224. View

Litvak A, Woo K, Hayes S, Huang J, Rimner A, Sima C . Clinical characteristics and outcomes for patients with thymic carcinoma: evaluation of Masaoka staging. J Thorac Oncol. 2014; 9(12):1810-5. PMC: 4663074. DOI: 10.1097/JTO.0000000000000363. View

Yang C, Hurd J, Shah S, Liou D, Wang H, Backhus L . A national analysis of open versus minimally invasive thymectomy for stage I to III thymoma. J Thorac Cardiovasc Surg. 2020; 160(2):555-567.e15. DOI: 10.1016/j.jtcvs.2019.11.114. View

Nakagawa K, Yokoi K, Nakajima J, Tanaka F, Maniwa Y, Suzuki M . Is Thymomectomy Alone Appropriate for Stage I (T1N0M0) Thymoma? Results of a Propensity-Score Analysis. Ann Thorac Surg. 2015; 101(2):520-6. DOI: 10.1016/j.athoracsur.2015.07.084. View

Zhou M, Chen Y, Zhang J, Bai W, Huang C, Guo C . A systematic review and meta-analysis of thymic mucosa-associated lymphoid tissue lymphoma. J Thorac Dis. 2022; 14(8):2894-2907. PMC: 9442531. DOI: 10.21037/jtd-22-81. View

Yamashita H, Izutsu K, Nakamura N, Shiraishi K, Chiba S, Kurokawa M . Treatment results of chemoradiation therapy for localized aggressive lymphomas: A retrospective 20-year study. Ann Hematol. 2006; 85(8):523-9. DOI: 10.1007/s00277-006-0114-4. View

Martelli M, Ferreri A, Di Rocco A, Ansuinelli M, Johnson P . Primary mediastinal large B-cell lymphoma. Crit Rev Oncol Hematol. 2017; 113:318-327. DOI: 10.1016/j.critrevonc.2017.01.009. View

10.

Kent M, Wang T, Gangadharan S, Whyte R . What is the prevalence of a "nontherapeutic" thymectomy?. Ann Thorac Surg. 2013; 97(1):276-82. DOI: 10.1016/j.athoracsur.2013.07.121. View

11.

Ackman J, Verzosa S, Kovach A, Louissaint Jr A, Lanuti M, Wright C . High rate of unnecessary thymectomy and its cause. Can computed tomography distinguish thymoma, lymphoma, thymic hyperplasia, and thymic cysts?. Eur J Radiol. 2015; 84(3):524-533. DOI: 10.1016/j.ejrad.2014.11.042. View

12.

Byrd C, Trope W, Bhandari P, Konsker H, Moradi F, Lui N . Positron emission tomography/computed tomography differentiates resectable thymoma from anterior mediastinal lymphoma. J Thorac Cardiovasc Surg. 2022; 165(1):371-381.e1. DOI: 10.1016/j.jtcvs.2022.02.055. View

13.

Watanabe T, Shimomura H, Mutoh T, Saito R, Goto R, Yamada T . Positron emission tomography/computed tomography as a clinical diagnostic tool for anterior mediastinal tumors. Surg Today. 2018; 49(2):143-149. DOI: 10.1007/s00595-018-1712-1. View

14.

Kanou T, Funaki S, Minami M, Ose N, Kimura T, Fukui E . Usefulness of positron-emission tomography for predicting the World Health Organization grade of thymic epithelial tumors. Thorac Cancer. 2022; 13(11):1651-1656. PMC: 9161332. DOI: 10.1111/1759-7714.14434. View

15.

Shiiya H, Ujiie H, Hida Y, Kato T, Kaga K, Wakasa S . Elevated serum CYFRA 21-1 level as a diagnostic marker for thymic carcinoma. Thorac Cancer. 2021; 12(21):2933-2942. PMC: 8563155. DOI: 10.1111/1759-7714.14158. View

16.

Mimori T, Shukuya T, Ko R, Okuma Y, Koizumi T, Imai H . Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study. Cancers (Basel). 2022; 14(2). PMC: 8773938. DOI: 10.3390/cancers14020331. View

17.

Falkson C, Vella E, Ellis P, Maziak D, Ung Y, Yu E . Surgical, Radiation, and Systemic Treatments of Patients With Thymic Epithelial Tumors: A Clinical Practice Guideline. J Thorac Oncol. 2022; 17(11):1258-1275. DOI: 10.1016/j.jtho.2022.08.007. View

18.

Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S . Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5:v40-55. DOI: 10.1093/annonc/mdv277. View

19.

Kim S, Bull D, Hsu C, Hsu C . The Role of Adjuvant Therapy in Advanced Thymic Carcinoma: A National Cancer Database Analysis. Ann Thorac Surg. 2019; 109(4):1095-1103. DOI: 10.1016/j.athoracsur.2019.11.009. View

20.

Cheufou D, Valdivia D, Puhlvers S, Fels B, Weinreich G, Taube C . Lymph Node Involvement and the Surgical Treatment of Thymic Epithelial and Neuroendocrine Carcinoma. Ann Thorac Surg. 2019; 107(6):1632-1638. DOI: 10.1016/j.athoracsur.2019.01.006. View